Apr 15 |
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
|
Apr 15 |
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
|
Apr 8 |
Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
|
Apr 4 |
Viatris- Theramex deal for women's care products raises antitrust concerns in U.K.
|
Apr 4 |
Competition watchdog says HRT drug deal could raise prices
|
Apr 4 |
UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns
|
Apr 1 |
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
Apr 1 |
Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent
|
Apr 1 |
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
Apr 1 |
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
|